NASDAQ · Biotechnology

Akero Therapeutics, Inc. (AKRO) Stock

$54.65 +0.00% NASDAQ: AKRO Healthcare

Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH).

Valuation

MetricValue
Price$54.65
Market Cap$4.50B
P/E Ratio-19.87
P/B Ratio4.68
P/S Ratio0.00
EPS (TTM)$-3.75
52-Week High$58.40
52-Week Low$21.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-21.79%
ROA-22.16%
ROCE-26.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio15.83

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-80.0M$-101.0M$-115.0M$-173.0M$-285.0M
Net Profit$-79.0M$-101.0M$-112.0M$-152.0M$-252.0M
EPS$-2.52$-2.89$-2.87$-2.89$-3.75
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$273.0M$196.0M$357.0M$580.0M$826.0M
Total Liabilities$15.0M$26.0M$30.0M$45.0M$76.0M
Cash$187.0M$150.0M$250.0M$234.0M$340.0M
Borrowings$2.0M$2.0M$11.0M$26.0M$36.0M

Latest News

Net Asset Value(s) Business Wire · Jul 14, 2026 Is your advisor scaring you into buying an annuity after saving for retirement? Here’s where you should tell them to go Moneywise · Jul 14, 2026 Barings BDC, Inc. Announces Conference Call to Discuss Second Quarter 2026 Results Business Wire · Jul 14, 2026 BYD, Covestro agree long-term collaboration on advanced materials Just Auto · Jul 14, 2026 Key Players in Remote Data Center Disaster Recovery: Veeam, Zerto, IBM, Microsoft Azure, and AWS Lead the Charge GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-71.0M$-80.0M$-93.0M$-145.0M$-230.0M
Investing Cash Flow$-10.0M$42.0M$-64.0M$-224.0M$-111.0M
Financing Cash Flow$1.0M$0$4.0M$3.0M$13.0M
Net Cash Flow$123.0M$-37.0M$99.0M$-16.0M$106.0M
Free Cash Flow$-71.0M$-80.0M$-93.0M$-145.0M$-231.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-88.50
EV / EBITDA-19.71
FCF Yield-4.07%
Quick Ratio15.83
Interest Coverage-73.72
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $29.21 +2.67% 8.94 $5.00B 0.00%
ACLXArcellx, Inc. $115.07 +0.02% -28.27 $6.73B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
IMVT $39.24 +1.91% -11.09 $8.06B 0.00%

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.

Akero Therapeutics, Inc. is headquartered in US.

Akero Therapeutics, Inc. (AKRO) stock trades at $54.65 with a market capitalization of $4.50B. The stock is valued at a price-to-earnings (P/E) ratio of -19.87, price-to-book of 4.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $21.34 and $58.40, and currently trades 6.4% below its 52-week high.

On profitability, Akero Therapeutics, Inc. generates a return on equity (ROE) of -21.79%, return on capital employed of -26.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.akerotx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides